Initiatives to improve prescribing efficiency for drugs to treat Parkinson's disease in Croatia: Influence and future directions

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 3, 2012, Pages 373-384

  Brkicic, Ljiljana Sovic ^a   Godman, Brian ^b,c   Voncina, Luka ^d   Sovic, Slavica ^e   Relja, Maja ^e  

^a Croatian Institute for Health Insurance   (Croatia)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d Ministry of Health   (Croatia)

^e UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Croatia; drug utilization studies; generics; health policy; Parkinson's disease; pharmacoepidemiology; reforms

Indexed keywords

AMANTADINE; BENSERAZIDE; BIPERIDEN; BROMOCRIPTINE; CARBIDOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR BLOCKING AGENT; ENTACAPONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PRAMIPEXOLE; PROTON PUMP INHIBITOR; RASAGILINE; ROPINIROLE; SELEGILINE;

ARTICLE; BRADYKINESIA; CROATIA; DRUG COST; DRUG UTILIZATION; DYSKINESIA; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MOTOR DYSFUNCTION; OBSERVATIONAL STUDY; PARKINSON DISEASE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; REIMBURSEMENT; RETROSPECTIVE STUDY; RIGIDITY; SYMPTOMATOLOGY; TREMOR;

ADULT; ANTIPARKINSON AGENTS; CROATIA; DATABASES, FACTUAL; DRUG COSTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; PARKINSON DISEASE; PATENTS AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES;

EID: 84864199542     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.24     Document Type: Article

References (70)

1. Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France: Implications for key stakeholder groups. Appl. Health Econ. Health Policy 8(1), 7-24 (2010
2. Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V. Recent national and regional drug reforms in Sweden: Implications for pharmaceutical companies in Europe. Pharmacoeconomics 26(7), 537-550 (2008
3. Godman B, Shrank W, Wettermark B et al. Use of generics - a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3, 2470-2494 (2010
4. Coma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: Impact and future direction. Expert Rev. Pharmacoecon. Outcomes Res. 9(6), 569-581 (2009
5. Godman B, Shrank W, Andersen M et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: Changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10(6), 707-722 (2010
6. Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfried H, Wieninger P. Insight into recent reforms and initiatives in Austria: Implications for key stakeholders. Expert Rev. Pharmacoecon. Outcomes Res. 8(4), 357-371 (2008
7. Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing efficiency in Europe: Findings and future implications. Frontiers Pharmacol. 1(141), 1-16 (2011
8. Voncina L, Strizrep T, Godman B et al. Influence of demand side measures to enhance renin-angiotensin prescribing efficiency in Europe; implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 11(4), 469-479 (2011
9. Garattini S, Bertele' V, Godman B, Haycox A, Wettermark B, Gustafsson LL; Piperska Group. Enhancing the rational use of new medicines across European health care systems. Eur. J. Clin. Pharmacol. 64(12), 1137-1138 (2008
10. Godman B, Wettermark B, Bishop I et al European payer initiatives to reduce prescribing costs through use of generics. GaBI 1, 22-27 (2012
11. Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev. Pharmacoecon. Outcomes Res 12(1), 125-130 (2012
12. Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: Implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 9(5), 475-484 (2009
13. Voncina L, Strizrep T. Croatia: 2009/2010pharmaceutical pricing and reimbursement reform. Eurohealth 16, 20-22 (2011
14. Voncina L, Strizrep T, Godman B, Vlahovic-Palcevski V. Recent policies to enhance prescribing efficiency in Croatia: Their impact and future guidance. Pharmacoepidemiol. Drug Saf. 20, S209 (2011
15. Voncina L, Strizrep T, Bagat M, Pezelj-Duliba D, Pavic N. Croatian 2008-2010 health insurance reform: Hard choices toward financial sustainability and efficiency. Croat. Med. J. 53(1), 66-76 (2012
16. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp FM. Soft regulations in pharmaceutical policy making: An overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7(3), 137-147 (2009
17. Godman B, Malmström RE, Bennie M et al. Prescribing restrictions - a necessary strategy among some European countries to enhance future prescribing efficiency? Rev. Health Care 3, 5-16 (2012
18. Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26(2), 91-98 (2008)
19. Oertel WH, Quinn NP. Parkinsonism. In: Neurological Disorders: Course and Treatment Brandt T, Diener HC, Caplan LR (Eds)Academic Press, CA, USA, 715-772 (2003
20. Spottke AE, Reuter M, Machat O et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 23(8), 817-836 (2005
21. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1(8007), 345-349 (1977
22. Lindgren P. Economic evidence in Parkinson's disease: A review. Eur. J. Health Econ. 5 (Suppl. 1)63-66 (2004
23. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342(20), 1484-1491 (2000
24. Trifirò G, Savica R, Morgante L et al. Prescribing pattern of anti-Parkinson drugs in Southern Italy: Cross-sectional analysis in the years 2003-2005. Parkinsonism Relat. Disord. 14(5), 420-425 (2008
25. Oertel WH, Quinn NP. Parkinson's disease: Drug therapy. Baillieres Clin. Neurol. 6(1), 89-108 (1997
26. Askmark H, Antonov K, Aquilonius SM. The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption - a nation-wide perspective in Sweden. Parkinsonism Relat. Disord. 9(5), 271-276 (2003
27. Münchau A, Bhatia KP. Pharmacological treatment of Parkinson's disease. Postgrad. Med. J. 76(900), 602-610 (2000
28. Brooks DJ. Dopamine agonists: Their role in the treatment of Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 68(6), 685-689 (2000
29. Lees A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 22(9), 731-740 (2005
30. Magyar K. The pharmacology of selegiline Int. Rev. Neurobiol. 100, 65-84 (2011
31. Yasar S, Bergman J. Amphetamine-like effect of l-deprenyl (selegiline)in drug discrimination studies. Clin. Pharmacol. Ther. 56(6 Pt 2), 768-773 (1994
32. Parashos SA, Swearingen CJ, Biglan KM et al.; NET-PD Investigators. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD)Experience. Arch. Neurol. 66(9), 1099-1104 (2009
33. Clarke CE. Parkinson's disease. BMJ 335(7617), 441-445 (2007
34. Leoni O, Martignoni E, Cosentino M et al. Drug prescribing patterns in Parkinson's disease: A pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol. Drug Saf. 11(2), 149-157 (2002
35. Menniti-Ippolito F, Spila-Alegiani S, Vanacore N et al. Estimate of parkinsonism prevalence through drug prescription histories in the province of Rome, Italy. Acta Neurol. Scand. 92(1), 49-54 (1995
36. Lai BC, Schulzer M, Marion S, Teschke K, Tsui JK. The prevalence of Parkinson's disease in British Columbia, Canada, estimated by using drug tracer methodology. Parkinsonism Relat. Disord. 9(4), 233-238 (2003)
37. Norman C, Zarrinkoub R, Hasselström J, Godman B, Granath F, Wettermark B. Potential savings without compromising the quality of care. Int. J. Clin. Pract. 63(9), 1320-1326 (2009
38. Rønning M, Blix HS, Harbø BT, Strøm H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose - are drug utilisation data comparable? Eur. J. Clin. Pharmacol. 56(9-10), 723-727 (2000
39. Vlahovic-Palcevski V, Gantumur M, Radosevic N, Palcevski G, Vander Stichele R. Coping with changes in the defined daily dose in a longitudinal drug consumption database. Pharm. World Sci. 32(2), 125-129 (2010
40. Vlaar A, Hovestadt A, Van Laar T, Bloem BR. The treatment of early Parkinson's disease: Levodopa rehabilitated. Pract. Neurol 11(3), 145-152 (2011
41. Zapia M, Colosimo C, Levodopa PW. Back to the future. J. Neurol. 257(Suppl. 2) 247-248 (2010
42. Hornykiewicz O. A brief history of levodopa. J. Neurol. 257(Suppl. 2), 249-252 (2010
43. Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 21(8), 677-692 (2007
44. Waldvogel D. [Medical treatment of Parkinson's disease]. Ther. Umsch. 64(1), 15-20 (2007
45. Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in adVanced Parkinson's disease: A meta analysis. Int. J. Clin. Pract. 63(4), 613-623 (2009
46. Radad K, Gille G, Rausch WD. Short review on dopamine agonists: Insight into clinical and research studies releVant to Parkinson's disease Pharmacol. Rep. 57(6), 701-712 (2005
47. Kondo T. Initial therapy for Parkinson's disease: Levodopa vs. dopamine receptor agonists. J. Neurol. 249(Suppl. 2), II25-II29 (2002)
48. Clarke CE, Speller JM, Clarke JA. Pramipexole versus bromocriptine for levodopa-induced complications in parkinson's disease. Cochrane Database Syst. Rev. 3, CD002259 (2000
49. Clarke CE, Deane KH. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst. Rev.1, CD001517 (2001
50. Earley CJ. Clinical practice. Restless legs syndrome. N. Engl. J. Med. 348(21), 2103-2109 (2003
51. Gazette of the Croatian Government. Ordinance establishing the criteria for wholesale pricing of medical products and the method for reporting wholesale prices. National Gazette, 28th December (2009
52. Gazette of the Croatian Government. Ordinance for the criteria establishing National Drug Reimbursement List and Supplementary Drug List. National Gazette, 28th December (2009
53. Gazette of the Croatian Government. Ordinance amending the corrections of Ordinance establishing the criteria for wholesale pricing of medical products and the method for reporting wholesale prices. National Gazette, 17th February (2010
54. Gazette of the Croatian Government. Decision of establishing Particularly Expensive Drug List based on Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 10th February (2010
55. Gazette of the Croatian Government. Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 7th June (2010
56. Gazette of the Croatian Government. Decision of establishing Supplementary Drug List of the Croatian Institute for Health Insurance. National Gazette, 7th June (2010
57. Gazette of the Croatian Government Decision of establishing Particularly Expensive Drug List based on decision of establishing National Drug Reimbursement ist of the Croatian Institute for Health Insurance. National Gazette, 7th June (2010
58. Gazette of the Croatian Government. Correction of Decision of establishing Particularly Expensive Drug List based on Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 19th June (2010
59. Gazette of the Croatian Government. Correction of Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 5th July (2010
60. Gazette of the Croatian Government. Correction of Decision of establishing Supplementary Drug List of the Croatian Institute for Health Insurance. National Gazette, 5th July (2010
61. Gazette of the Croatian Government. Decision of correction of Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 24th November (2010
62. Gazette of the Croatian Government. Decision of correction of Decision of establishing Supplementary Drug List of the Croatian Institute for Health Insurance. National Gazette, 24th November (2010
63. Gazette of the Croatian Government. Decision of establishing Particularly Expensive Drug List based on Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 24th November (2010
64. Gazette of the Croatian Government. Decision of correction of Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 3rd January (2011
65. Gazette of the Croatian Government. Decision of correction of Decision of establishing Supplementary Drug List of the Croatian Institute for Health Insurance. National Gazette, 3rd January (2011
66. Gazette of the Croatian Government. Decision of corrections of Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 13th May (2011
67. Gazette of the Croatian Government Decision of corrections of Decision of establishing Supplementary Drug List of the Croatian Institute for Health Insurance. National Gazette, 13th May (2011
68. Gazette of the Croatian Government. Decision of corrections of Decision of establishing Particularly Expensive Drug List based on Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 13th May (2011
69. Gazette of the Croatian Government. Decision of corrections of Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 3rd June (2011
70. Gazette of the Croatian Government. Decision of corrections of Decision of establishing Particularly Expensive Drug List based on Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 10th August (2011)